Seattle Genetics continues to monitor the potential impact of the COVID-19 global pandemic across our business, and we will adjust our approach as necessary.

**SUPPLY OF OUR MEDICINES**
We are always working to ensure the stability of our supply chain. At this time, we do not anticipate disruptions to the supply of our medicines due to COVID-19, including our two marketed products, ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-efjv).

**COMMERCIAL**
Given the ongoing nature of the pandemic, our field-based personnel have paused in-person customer interactions in healthcare settings and are using digital means of ensuring continued support for healthcare professionals and patients. We continue to work closely with our partner, Astellas, to support a strong launch of PADCEV.

**EMPLOYEES**
The health and safety of our workforce is of the utmost importance and we’ve implemented measures to protect the health and safety of our workforce. These measures include a mandatory work-from-home policy for employees who can perform their jobs offsite. Our essential research and laboratory activities are ongoing, and we have taken a number of additional precautionary measures to protect employees whose jobs require they be on site.

**REGULATORY**
The FDA and other regulatory agencies continue to be actively engaged with us on a variety of matters. Importantly, the tucatinib New Drug Application is under ongoing review by FDA with a PDUFA action date of August 20, 2020.

**CLINICAL TRIALS**
We are focused on improving the lives of patients with cancer and many of our trials provide an option for patients where no standard of care exists. We are working diligently to advance our clinical trial activities, while ensuring the safety of our patients and clinical trial site personnel and maintaining trial integrity. We expect that some of our clinical trials will be affected by the capacity of health care institutions in certain regions with rapid growth of COVID-19 cases. We will continue to review new information about COVID-19, including recent guidance from regulators. We are working with investigators for the appropriate care for patients in line with agency guidelines.

**Forward Looking Statements**
Certain statements made in this fact sheet are forward looking, such as those, among others, relating to the research, development and commercialization of our products and product candidates, our manufacturing and product supply, workforce, sales and sales efforts, clinical trial activities and the COVID-19 pandemic. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties regarding the global spread and impact of the COVID-19 pandemic and its potential impacts on our business. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption “Risk Factors” included in the company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.